In our December 2019 issue, read about biomarkers in combinations of radiotherapy with immunotherapy, comorbidities in patients with cancer, phase I clinical trials and cancer staging.

In our November 2019 issue, read about therapeutic advances for patients with chronic lymphocytic leukaemia or head and neck cancer, and about the opportunities and challenges associated with using artificial intelligence in pathology and oncology.

Read about tumour-associated neutrophils in cancer, individualized therapy for metastatic renal cell carcinoma, and clinical genetics for diffuse large B cell lymphoma in our October 2019 issue.

Read about paraneoplastic neurological syndromes, adverse effects of immune-checkpoint inhibitors, therapeutic resistance in melanoma, and oligometastatic disease in our September 2019 issue.

COVER: In the August issue, read about the patient’s perspective on drug development, vessel co-option in cancer, epigenetic-modulating approaches for the treatment of lymphoma and the challenges of curing primary brain tumours.

The July issue features Reviews on tracking minimal residual disease with liquid biopsies, the interplay between metabolism and antitumour immunity and monitor therapeutic response with imaging.

Read about optimal design of and use of biomarkers in oncology trials, regulatory T cells, resistance to CAR T cell therapy and germline alterations in cancer.

Read about the role of CRISPR–Cas, real-world data and surgeon-driven research in oncology studies, and about tumour dormancy in breast cancer.

Read about aspects of paediatric cancer management, multidisciplinary team meetings, nonmedical opioid use in cancer, and clinical applications of imaging and proteomics.

Topics covered in this issue include immunoediting and resistance to therapy, active surveillance approaches and clinical development of antimetastatic agents.

This issue includes the Year in Review 2017 articles and also articles about DNA damage, FGF signalling and the abscopal effect.

Read management guidelines for paediatric patients receiving CAR T cell therapy and reviews on pancreatic cancer surgery and breast cancer adjuvant therapy.